ArticleResearch square2023

Targeting GD2-positive Refractory/Resistant Neuroblastoma and Osteosarcoma with Anti- CD3 x Anti-GD2 Bispecific Antibody Armed T cells.

Maxim Yankelevich et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.